Literature DB >> 25086189

Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study.

Christine Rungoe1, Jacob Simonsen1, Lene Riis2, Morten Frisch1, Ebbe Langholz3, Tine Jess4.   

Abstract

BACKGROUND & AIMS: We examined the risk of cervical neoplasia (dysplasia or cancer) in women with ulcerative colitis (UC) or Crohn's disease (CD). We also calculated the reverse, the risk for diagnosis with cervical neoplasia before development of inflammatory bowel disease (IBD).
METHODS: We established a national cohort of women diagnosed with UC (n = 18,691) or CD (n = 8717) between 1979 and 2011 and a control cohort of individually matched women from the general population (controls, n = 1,508,334). Incidence rate ratios (IRRs) of screening activity and diagnosis of cervical neoplasia in women with IBD were assessed by Cox proportional hazards regression analysis. Odds ratios (ORs) of cervical neoplasia before diagnosis of IBD were calculated by using conditional logistic regression.
RESULTS: Women with CD underwent cervical cancer screening as often as women in the general population (IRR, 0.99; 95% confidence interval [CI], 0.96-1.02), whereas screening frequency was slightly increased in women with UC (IRR, 1.06; 95% CI, 1.04-1.08). A total of 561 patients with UC were diagnosed with dysplasia during a median follow-up time of 7.8 years, and 28 patients with UC developed cervical cancer, compared with 1918 controls. A total of 407 patients with CD were diagnosed with dysplasia during a median follow-up time of 8.3 years, and 26 patients with CD developed cervical cancer, compared with 940 controls. Patients with UC had increased risk of low-grade (IRR, 1.15; 95% CI, 1.00-1.32) and high-grade (IRR, 1.12; 95% CI, 1.01-1.25) squamous intraepithelial lesions (SILs), whereas patients with CD had increased risks of low-grade SIL (IRR, 1.26; 95% CI, 1.07-1.48), high-grade SIL (IRR, 1.28; 95% CI, 1.13-1.45), and cervical cancer compared with controls (IRR, 1.53; 95% CI, 1.04-2.27). ORs for cervical cancer were also increased 1-9 years before diagnosis of UC, compared with women without UC (OR, 2.78; 95% CI, 2.12-3.64) or CD (OR, 1.85; 95% CI, 1.08-3.15).
CONCLUSIONS: In a population-based nationwide cohort study, we found a 2-way association between IBD, notably CD, and neoplastic lesions of the uterine cervix. This observation is not explained by differences in screening activity.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer Risk Factor; Neoplasia; Thiopurines; Treatment

Mesh:

Year:  2014        PMID: 25086189     DOI: 10.1016/j.cgh.2014.07.036

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  20 in total

1.  Preventive care for a 35-year-old woman with inflammatory bowel disease.

Authors:  Neeraj Narula; A Hillary Steinhart
Journal:  CMAJ       Date:  2017-02-13       Impact factor: 8.262

Review 2.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

4.  Sex-Specific Issues in Inflammatory Bowel Disease.

Authors:  Elizabeth Rosenblatt; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-09

Review 5.  Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.

Authors:  H Matthew Cohn; Maneesh Dave; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

6.  Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis.

Authors:  Jessica R Allegretti; Edward L Barnes; Anna Cameron
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

7.  Vaccinating Patients With Inflammatory Bowel Disease.

Authors:  Jason Reich; Sharmeel Wasan; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-09

Review 8.  Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?

Authors:  Jason S Reich; Francis A Farraye; Sharmeel K Wasan
Journal:  Dig Dis Sci       Date:  2016-04-09       Impact factor: 3.199

Review 9.  Monitoring for Extra-Intestinal Cancers in IBD.

Authors:  H Sifuentes; S Kane
Journal:  Curr Gastroenterol Rep       Date:  2015-11

Review 10.  Updates on Women's Health Issues in Patients with Inflammatory Bowel Disease.

Authors:  Nirupama Bonthala; Sunanda Kane
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.